Sharemaestro company-news research for AstraZeneca PLC (AZN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

BUE Argentina Measured evidence

Company news sentiment

AZN news sentiment

AstraZeneca PLC

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report RSS feed
30-day score55Neutral is 50
Balanced news tone 42/100 evidence confidence 98% direct company focus 28 current stories across 18 publishers
Latest weekly closeARS 63825.00week of 7 Aug 2026
Main news subjectDeals and strategy69/100 share of current news
News data statusHealthy17 duplicate stories removed

Current company news

Balanced news tone

The score uses 28 current company stories from 18 publishers.

Observed headline tone58/100 Published 30-day score55/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline How AstraZeneca’s $400bn deal unravelled finance.yahoo.com · 12 Aug 2026 04:00

What supports the score

Direct evidence

28 current stories are mapped specifically to AZN.

Source breadth

The score uses 18 publishers rather than depending on one outlet.

Story agreement

The current stories agree at 85/100.

What limits the score

Price disagreement

Price is moving more forcefully than the current news tone suggests.

55/100
News scoreBalanced news tone
42/100
Confidencebuilding confidence
98%/100
Company news28 company stories
85/100
Story agreement15/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
16 Jul: 1 stories20 Jul: 2 stories21 Jul: 1 stories23 Jul: 2 stories24 Jul: 2 stories27 Jul: 1 stories29 Jul: 1 stories30 Jul: 1 stories02 Aug: 2 stories03 Aug: 2 stories05 Aug: 1 stories07 Aug: 2 stories08 Aug: 1 stories10 Aug: 2 stories11 Aug: 6 stories12 Aug: 1 stories 16 Jul: tone 50, 1 stories20 Jul: tone 37, 2 stories21 Jul: tone 43, 1 stories23 Jul: tone 44, 2 stories24 Jul: tone 50, 2 stories27 Jul: tone 50, 1 stories29 Jul: tone 50, 1 stories30 Jul: tone 50, 1 stories02 Aug: tone 50, 2 stories03 Aug: tone 54, 2 stories05 Aug: tone 40, 1 stories07 Aug: tone 56, 2 stories08 Aug: tone 50, 1 stories10 Aug: tone 79, 2 stories11 Aug: tone 52, 6 stories12 Aug: tone 76, 1 stories 95505
16 Jul31 Jul14 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence25
1.238 after freshness weighting
Source breadth100
18 independent publishers
Company relevance98
share tied directly to this company
Freshness49
recency-weighted evidence
Agreement85
how closely stories agree
Publisher mix68
less reliance on one publisher

Price and news history

News score and weekly price over 26 weeks

Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb 2026: close 75274.45, indexed 100.020 Feb 2026: close 74425.0, indexed 98.927 Feb 2026: close 76275.0, indexed 101.306 Mar 2026: close 72100.0, indexed 95.813 Mar 2026: close 70000.0, indexed 93.020 Mar 2026: close 67500.0, indexed 89.727 Mar 2026: close 69725.0, indexed 92.603 Apr 2026: close 74600.0, indexed 99.110 Apr 2026: close 75425.0, indexed 100.217 Apr 2026: close 74975.0, indexed 99.624 Apr 2026: close 70875.0, indexed 94.201 May 2026: close 70525.0, indexed 93.708 May 2026: close 67750.0, indexed 90.015 May 2026: close 67325.0, indexed 89.422 May 2026: close 69825.0, indexed 92.829 May 2026: close 68850.0, indexed 91.505 Jun 2026: close 70125.0, indexed 93.212 Jun 2026: close 66925.0, indexed 88.919 Jun 2026: close 65900.0, indexed 87.526 Jun 2026: close 72625.0, indexed 96.503 Jul 2026: close 79499.12, indexed 105.610 Jul 2026: close 66903.48, indexed 88.917 Jul 2026: close 66058.8, indexed 87.824 Jul 2026: close 67102.23, indexed 89.131 Jul 2026: close 66555.67, indexed 88.407 Aug 2026: close 63825.0, indexed 84.8 19 Jun 2026: news score 51, close 65900.0, 5 stories5126 Jun 2026: news score 50, close 72625.0, 13 stories03 Jul 2026: news score 50, close 79499.12, 17 stories5010 Jul 2026: news score 46, close 66903.48, 24 stories17 Jul 2026: news score 47, close 66058.8, 29 stories4724 Jul 2026: news score 47, close 67102.23, 27 stories31 Jul 2026: news score 48, close 66555.67, 24 stories4807 Aug 2026: news score 50, close 63825.0, 27 stories50
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
26-week price-15.2%latest close 63825.0
News score change-1first to latest comparable week
One-week response-4.1%Price reacting lower
Fair-value position+55.9%Materially above fair value
WeekNews scoreCloseWeekly move
07 Aug 202650ARS 63825.0-4.1%
31 Jul 202648ARS 66555.67-0.8%
24 Jul 202647ARS 67102.23+1.6%
17 Jul 202647ARS 66058.8-1.3%
10 Jul 202646ARS 66903.48-15.8%
03 Jul 202650ARS 79499.12+9.5%
26 Jun 202650ARS 72625.0+10.2%
19 Jun 202651ARS 65900.0-1.5%

News subjects

What is shaping the score

Deals and strategy
Market update577 stories · 25%
Deals and strategy467 stories · 25%
Earnings695 stories · 18%
Balance sheet413 stories · 11%
Analyst action742 stories · 7%
Guidance562 stories · 7%
Regulatory and legal532 stories · 7%

Source mix

Where the evidence comes from

68/100 independence
finance.yahoo.com657 stories · 25%
GuruFocus633 stories · 11%
Traders Union562 stories · 7%
seekingalpha.com502 stories · 7%
simplywall.st251 stories · 4%
PR Newswire351 stories · 4%
DirectorsTalk Interviews631 stories · 4%

Recurring subjects

Subjects appearing most often

Current evidence
Pharma4Earnings4Oncology3M A3Biotech3Price Target2Fda Approval2Earnings Per Share2Trials1Split1

Earlier readings

How the score has changed

37 comparable readings · 56 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+751 to 58 · Strengthening
Observed range46–5850 is the neutral baseline
Evidence depth39stories at latest stored reading · +36
Confidence46/100Measured · +15
18 Jun50 neutral14 Aug 01:14
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
14 Aug 01:1458+046/100 (-4)39 (-1)Measured
12 Aug 23:5958+050/100 (-2)40 (0)Measured
11 Aug 23:5958+152/100 (+8)40 (+7)Measured
10 Aug 23:5957+244/100 (+2)33 (+3)Measured
09 Aug 23:5955+542/100 (+3)30 (+1)Measured
08 Aug 23:5950+039/100 (+2)29 (+2)Measured
07 Aug 23:5950+237/100 (+5)27 (+1)Measured
05 Aug 23:5948-132/100 (-1)26 (-1)Provisional

Source headlines

The news behind the score

Showing 1-28 of 28

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#176Tone
finance.yahoo.comDirect company coverageStored article

How AstraZeneca’s $400bn deal unravelled

One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now

Published
12 Aug 2026 04:00
News subject
Analyst action
Why this score
Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 10.1% · 1.9d old
Duplicates
1 consolidated
#240Tone
finance.yahoo.comDirect company coverageStored article

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti

M AOncologyPatent ExpiryPharmaSplit
Published
11 Aug 2026 19:34
News subject
Deals and strategy
Why this score
Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 9.1% · 2.2d old
Duplicates
1 consolidated
#350Tone
finance.yahoo.comDirect company coverageStored article

Do Options Traders Know Something About AstraZeneca Stock We Don't?

Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. Ho

BiotechImplied VolatilityOptions Trading
Published
11 Aug 2026 14:11
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2% · 2.5d old
Duplicates
1 consolidated
#462Tone
finance.yahoo.comDirect company coverageStored article

Hedge Funds are Bullish on AstraZeneca PLC (AZN)

AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the W

EarningsEarnings Per ShareOncologyPharmaRegulationTrials
Published
11 Aug 2026 14:04
News subject
Earnings
Why this score
Beat expectations
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 10.4% · 2.5d old
Duplicates
1 consolidated
#550Tone
seekingalpha.comDirect company coverageStored article

Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves

Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF [https://seekingalpha.com/symbol/RYKKF]), Mitsubishi UFJ Financial Group (MUFG [https://seekingalpha.com/symbol/MUFG]), Tokio Marine Holdings (TKOMF [https://seekingalpha.com/symbol/TKOMF]), AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), Nokia (NOK [https://seekingalpha.com/symbol/NOK]), Rent

EarningsFinancialsHealthcareRevenue Growth
Published
11 Aug 2026 13:36
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Company discussed · 86%
How it is used
Direct company coverage
Weighted influence
Low · 4.7% · 2.5d old
Duplicates
1 consolidated
#650Tone
finance.yahoo.comDirect company coverageStored article

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion rare-disease platform. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and BioCryst Pharmaceuticals didn't make the cut. Grab the names FREE today. BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a m

BiotechEarningsFree Cash FlowGuidanceM AOperating Income
Published
11 Aug 2026 13:20
News subject
Deals and strategy
Why this score
No clear positive or negative phrase
Company focus
Company discussed · 86%
How it is used
Direct company coverage
Weighted influence
Low · 4.2% · 2.5d old
Duplicates
1 consolidated
#757Tone
Traders UnionDirect company coverageScored from headline

AstraZeneca stock outlook: Seller pressure limits upside for AZN

Published
11 Aug 2026 08:02
News subject
Guidance
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 8.4% · 2.7d old
Duplicates
1 consolidated
#881Tone
finance.yahoo.comDirect company coverageStored article

Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?

It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-hi

Balance SheetClinical TrialsDividendsEarningsEarnings GrowthEarnings Per Share
Published
10 Aug 2026 23:44
News subject
Earnings
Why this score
Beat expectations, Positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Medium · 15.8% · 3.1d old
Duplicates
1 consolidated
#1050Tone
seekingalpha.comDirect company coverageStored article

SA Asks: What's the outlook for Big Pharma M&A?

[Medical research with pipette and test tube, DNA analysis, biotechnology, genetic science and healthcare] jittawit.21 Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) was in merger talks with AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]), a development that was later denied by unnamed sources to Reuters. We asked Seeking Alpha analysts Stephen Ayers [https://seekingalpha.com/author/stephen-ayers], ALLKA Research [https://seekingalpha.com/author/allka-research], and Chris DeMuth

BiotechFda ApprovalM&aM AOncologyPharma
Published
08 Aug 2026 19:28
News subject
Deals and strategy
Why this score
No clear positive or negative phrase
Company focus
Company discussed · 86%
How it is used
Direct company coverage
Weighted influence
Low · 3.5% · 5.2d old
Duplicates
1 consolidated
#1167Tone
finance.yahoo.comDirect company coverageStored article

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. The upgrade helped send Roche's U.S.-traded ADRs up about 2.2% to $57.38 during Friday's session. Morgan Stanley also swapped out AstraZeneca as its top pharmaceutical pick in favor of Roche, a clear sign the bank believes the company's next growth story is gaining momentum. Warning! GuruFocus has detected 7 Warning Signs

Earnings EstimateFda ApprovalIntrinsic ValuePharmaPrice TargetPrice Target
Published
07 Aug 2026 19:30
News subject
Analyst action
Why this score
Analyst upgrade, Positive market reaction
Company focus
Company discussed · 86%
How it is used
Direct company coverage
Weighted influence
Low · 3.1% · 6.2d old
Duplicates
1 consolidated
#1250Tone
WSJDirect company coverageScored from headlineSource lookup

Deal or No Deal, AstraZeneca Stock Is a Bargain

Published
07 Aug 2026 06:39
News subject
Deals and strategy
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 5.1% · 6.8d old
Duplicates
1 consolidated
#1340Tone
TIKR.comDirect company coverageScored from headlineSource lookup

AstraZeneca Stock Drops 7% as Merger Talks With Bristol Myers Squibb Surface

Published
05 Aug 2026 05:39
News subject
Deals and strategy
Why this score
Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 4.5% · 8.8d old
Duplicates
1 consolidated
#1750Tone
MarketBeatDirect company coverageScored from headlineSource lookup

Astrazeneca (AZN) Short Interest & Short Float | Updated Aug 2026 $AZN

Published
02 Aug 2026 12:03
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 11.5d old
Duplicates
1 consolidated
#1850Tone
Quiver QuantitativeDirect company coverageScored from headlineSource lookup

Fund Update: 42,335 ASTRAZENECA (AZN) shares added to STEPHENS INC |AR| portfolio

Published
30 Jul 2026 06:49
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 14.8d old
Duplicates
1 consolidated
#1950Tone
MoomooDirect company coverageScored from headlineSource lookup

AstraZeneca (AZN) Cash Flow Statement

Published
29 Jul 2026 06:59
News subject
Balance sheet
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.6% · 15.8d old
Duplicates
1 consolidated
#2050Tone
GuruFocusDirect company coverageScored from headlineSource lookup

AstraZeneca (AZN) Earnings Report Anticipated as Wall Street Clo

Published
27 Jul 2026 00:29
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.5% · 18.0d old
Duplicates
1 consolidated
#2150Tone
GuruFocusDirect company coverageScored from headlineSource lookup

AstraZeneca PLC (LSE:AZN) Q2 2026: Everything You Need To Know A

Published
24 Jul 2026 18:40
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 20.3d old
Duplicates
1 consolidated
#2250Tone
Traders UnionDirect company coverageScored from headline

AstraZeneca stock forecast: Consolidation near GBX12,547 support

Published
24 Jul 2026 07:00
News subject
Guidance
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1% · 20.8d old
Duplicates
1 consolidated
#2367Tone
GuruFocusDirect company coverageScored from headlineSource lookup

AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance

Published
23 Jul 2026 12:13
News subject
Regulatory and legal
Why this score
Contract or approval won
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.9% · 21.5d old
Duplicates
1 consolidated
#2425Tone
simplywall.stDirect company coverageScored from headlineSource lookup

AstraZeneca Stock And 2 Value Picks Trading Below Cash Flow Estimates

Published
23 Jul 2026 09:01
News subject
Balance sheet
Why this score
Missed expectations
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2.3% · 21.7d old
Duplicates
1 consolidated
#2650Tone
The TimesDirect company coverageScored from headlineSource lookup

AstraZeneca needs a shot in the arm to hit $80bn revenue target

Published
20 Jul 2026 23:20
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.2% · 24.1d old
Duplicates
1 consolidated
#2735Tone
PR NewswireDirect company coverageScored from headlineSource lookup

AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky

Published
20 Jul 2026 16:31
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.6% · 24.4d old
Duplicates
1 consolidated
#2850Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup

AstraZeneca’s Oncology Engine Keeps Running Despite Wainua Setback (NYSE:AZN)

Published
16 Jul 2026 09:29
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 28.7d old
Duplicates
1 consolidated

Earlier company news

AZN news archive

Showing 1-26 of 26 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Aug 08 2026
finance.yahoo.comArchivedPositive tone

AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven too

Clinical TrialsOncologyPartnershipPharmaPrecision MedicineShare Price
Published
8 Aug 2026 16:12
Catalyst
Deals and strategy
Coverage
Direct company
Duplicates
1 consolidated
Jun 26 2026
TradingViewArchivedLegacy headline · tone unscoredLegacy source lookup

AstraZeneca PLC Actuals & Estimates (LSE:AZN)

Published
26 Jun 2026 11:38
Catalyst
Legacy snapshot
Coverage
Direct company
Duplicates
1 consolidated

Provider matches checked

Provider mentions not used in the score

18 not scored

A news provider linked these stories to AZN, but the headline and available text are not mainly about AstraZeneca PLC. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of AZN sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context